Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon—a Case-Matched Study

Badurdeen, Dilhana; Hoff, Anna Carolina; Barrichello, Sérgio A.; Hedjoudje, Abdellah; Itani, Mohamad I.; Farha, Jad; Abbarh, Shahem; Adam, Atif; Singh, Vikesh K.; Ngamruengphong, Saowanee; Oberbach, Andreas; Khashab, Mouen A.; Neto, Manoel Galvão; Kumbhari, Vivek

doi:10.1007/s11695-020-05117-8

Cited by 16 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the field of obesity management continues to evolve, including the development of promising medications such as newer GLP-1 receptor agonists and interventions such as duodenal mucosal resurfacing, many interventions lack long-term clinical use data compared with IGB, which have 3 decades of evidence 30,31 . Furthermore, studies have shown that combination therapy with IGB and weight loss medications results in increased efficacy, supporting a synergystic approach 32,33 . We find that in our practice, IGB therapy continues to serve a role as adjunctive therapy for patients who have tried other weight loss methods.…”

Section: Discussionmentioning

confidence: 84%

Comparison of the Efficacy and Safety of the FDA-approved Intragastric Balloon Systems in a Clinical Setting

Swei

Almuhaidb²,

Sullivan

et al. 2022

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Background and Aims: The gas-filled intragastric balloon (IGB) system (Obalon) and the fluid-filled IGB system (Orbera) are the current FDA-approved IGB systems to treat obesity; however, they have not been previously compared in clinical practice. The aims of this study were to compare their efficacy, tolerance, and safety in a clinical setting. Materials and Methods: This is a retrospective cohort study of consecutive patients treated with the gas-filled IGB or fluid-filled IGB between October 2015 and May 2020 at 2 academic centers. The primary endpoints included percent total body weight loss at balloon removal in patients who completed at least 20 weeks of therapy, the difference in adverse events that required urgent evaluation or hospitalization, and early removal in the 2 groups. Results: A total of 87 patients underwent successful IGB placement (gas-filled IGB n=57, age 48.9±8.8, body mass index 35.5±5 kg/m2; fluid-filled IGB n=30, age 49.2±14.3, body mass index 38.8±6 kg/m2). Eleven patients underwent early device removal. There were no differences in percent total body weight loss at balloon removal and 12 months between the balloon systems (P=0.39). Patients who received the fluid-filled IGB were more likely to require urgent evaluation or treatment, require hospital stay >24 hours, and need early balloon system removal compared with patients treated with the gas-filled IGB. Conclusion: In this 2-center cohort, both FDA-approved gastric balloon systems had the same effectiveness, but the gas-filled IGB had fewer serious adverse events and better tolerability than the fluid-filled IGB.

show abstract

Section: Discussionmentioning

confidence: 84%

Comparison of the Efficacy and Safety of the FDA-approved Intragastric Balloon Systems in a Clinical Setting

Swei

Almuhaidb²,

Sullivan

et al. 2022

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

“…6,7 EBMTs offer an innovative incisionless solution for the treatment of metabolic disease. As demonstrated in this study and other EBMT and GLP-1RA combination studies, 8,9 personalized, precision therapies 10 will likely be a part of the solution for obesity and metabolic disease. Given that obesity and metabolic disorders coexist in many if not most patients with overweight and obesity, the time has come to start combatting both weight and metabolic parameters with endoscopic therapies that target both issues in a safe and effective manner.…”

mentioning

confidence: 71%

Rejuvenate and repopulate: renaissance of the duodenum

Gómez

Badurdeen

Kumbhari

2021

Gastrointestinal Endoscopy

Self Cite

View full text Add to dashboard Cite

“…Disappointingly, TBWL and development of obesity related comorbidities were not significantly different in the two groups. In an attempt to improve the durability of weight loss, Badurdeen et al [31] assessed the effectiveness of initiating the GLP-1 agonist Liraglutide after balloon removal. In this propensity-matched study, there was significantly less weight regain in the IGB-Liraglutide arm when compared to the IGB only arm (À1.15 AE 0.94 kg vs. À0.66 AE 0.99 kg, P ¼ 0.010).…”

Section: Recent Data On Quality Of Life Improvement and Long-term Eff...mentioning

confidence: 99%

Endobariatrics: well past infancy and maturing rapidly

Shrestha

Shah

2022

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewThis review summarizes the key developments with regard to FDA-approved endoscopic bariatric metabolic therapies (EBMTs) in the last 2 years.Recent findingsThe prevalence of obesity has increased during the coronavirus disease 2019 (COVID-19) pandemic, and obesity worsens COVID-19 related outcomes. Several studies have confirmed the safety and short-term efficacy of intragastric balloons (IGBs). In the short-term IGBs may improve steatosis and fibrosis in nonalcoholic fatty liver disease and improve quality of life and mental health. Unfortunately weight loss from these temporarily placed devices is not sustained long-term. Endoscopic sleeve gastroplasty (ESG) may be more effective and durable than IGBs, and result in fewer adverse events compared to bariatric surgery. The recently completed MERIT trial may catapult ESG as a first-line EBMT. Aspiration therapy meets safety and effectiveness thresholds for incorporation into routine practice, but overall acceptance has been lower than other FDA-approved EBMTs.SummaryThe field of endobariatrics is rapidly maturing. Significant knowledge gaps remain with regards to combining EBMTs with pharmacologic therapy to improve durability of weight loss. The rapid expansion in the literature supporting safety and long-term efficacy ESG may prompt revision of existing guidelines.

show abstract

Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon—a Case-Matched Study

Cited by 16 publications

References 42 publications

Comparison of the Efficacy and Safety of the FDA-approved Intragastric Balloon Systems in a Clinical Setting

Comparison of the Efficacy and Safety of the FDA-approved Intragastric Balloon Systems in a Clinical Setting

Rejuvenate and repopulate: renaissance of the duodenum

Endobariatrics: well past infancy and maturing rapidly

Contact Info

Product

Resources

About